Chronic myeloid leukaemia Remission of polycythaemia vera

Essential thrombocythaemia and myelofibrosis

Conditioning before bone marrow transplantation

Oral:

Chronic myeloid leukaemia: 60 mcg/kg daily (maximum 4 mg daily); maintenance: 0.5–2 mg daily

Polycythaemia vera: 4–6 mg daily; maintenance: 2–3 mg daily

Myelofibrosis: 2–4 mg daily

Conditioning before bone marrow transplantation: 0.8 mg/kg every 6 hours over 4 days for 16 doses

Molecular weight :246.3

%Protein binding :7–32

%Excreted unchanged in urine : 1–2

Volume of distribution (L/kg) :0.62–0.85

half-life – normal/ESRD (hrs) :3/–

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

CAPD :Unknown dialysability. Dose as in normal renal function

HD :Dialysed. Dose as in normal renal function

HDF/high flux :Dialysed. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

Potentially hazardous interactions with other drugs

Antibacterials: concentration increased by metronidazole

Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis

Antifungals: metabolism inhibited by itraconazole, monitor for signs of busulfan toxicity

–

Oral,

Over 2 hours

Dilute the solution to 500 mcg/mL with sodium chloride or glucose 5%Give via a central venous catheter

Can cause haemorrhagic cystitis

Can cause an increase in creatinine and haematuria.